{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:15:10Z","timestamp":1778656510368,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Occult breast carcinoma (OBC) refers to the clinical presentation of breast carcinoma occurring in axillary lymph node(s) without a detectable primary breast cancer. Prior studies of OBC have focused on treatment regimens. We sought to study the clinical, morphologic, and immunohistochemical features of OBCs. We retrospectively identified cases of OBC treated at our center between 1996 and 2021. All patients included in the study had biopsy-proven axillary metastatic breast carcinoma and underwent MRI after a noncontributory mammogram\/ultrasound. Patients with a prior history of breast carcinoma were excluded. The study included 68 patients with a median age of 56 years (range: 31 to 84\u00a0y). The morphology in 55 cases (81%) was poorly-differentiated carcinoma, no special type (ductal). The remaining tumors showed lobular, micropapillary, apocrine, clear cell, and signet ring cell morphology. Thirty-nine (57.4%) OBC were hormone receptor positive, 19 (33.3%) were HER2 positive and 13 (22.8%) tumors were triple negative. Fifty (74%) patients had a breast sampling procedure while 18 (26%) did not. Thirty-four (50%) patients underwent neoadjuvant chemotherapy. Fifty-nine (87%) patients underwent axillary lymph node dissection while 9 (13%) had sentinel lymph node biopsy only. Nineteen (56%) patients achieved a complete pathologic response in the axilla. Fourteen (21%) patients developed a recurrence: 5 in the ipsilateral breast or axilla, 1 in the contralateral axilla and mediastinum, and 8 in distant metastatic sites. The median time to recurrence was 51.9 months. The final pathologic lymph node stage was the only feature found to be significantly associated with the development of recurrence.<\/jats:p>","DOI":"10.1097\/pas.0000000000002534","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:00:09Z","timestamp":1773212409000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Occult Breast Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Atif A.","family":"Hashmi","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"D\u2019Alfonso","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"El-Tamer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Grabenstetter","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"R1-20260513","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0970-9371.80740","article-title":"FNAB of metastatic lesions with special reference to clinicopathological analysis of primary site in cases of epithelial and non-epithelial tumors","volume":"28","author":"Ahmad","year":"2011","journal-title":"J Cytol"},{"key":"R2-20260513","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.breast.2020.10.012","article-title":"Occult breast cancer: where are we at?","volume":"54","author":"Ofri","year":"2020","journal-title":"Breast"},{"key":"R3-20260513","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3349\/ymj.2023.0181","article-title":"Analysis of prognoses according to breast MRI results in patients with axillary lymph node metastases from an unknown primary origin","volume":"64","author":"Choi","year":"2023","journal-title":"Yonsei Med J"},{"key":"R4-20260513","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","article-title":"Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review","volume":"36","author":"de Bresser","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"R5-20260513","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1245\/s10434-017-5965-5","article-title":"Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+)","volume":"24","author":"McCartan","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R6-20260513","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1245\/s10434-020-08863-2","article-title":"Axillary downstaging in occult primary breast cancer after neoadjuvant chemotherapy","volume":"28","author":"Botty Van den Bruele","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R7-20260513","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2217\/fon-2023-0685","article-title":"Occult breast cancer patients with mastectomy have better prognosis than those with breast-conserving therapy","volume":"19","author":"Li","year":"2023","journal-title":"Future Oncol"},{"key":"R8-20260513","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1002\/cncr.25197","article-title":"Population-based analysis of occult primary breast cancer with axillary lymph node metastasis","volume":"116","author":"Walker","year":"2010","journal-title":"Cancer"},{"key":"R9-20260513","doi-asserted-by":"crossref","first-page":"1051232","DOI":"10.3389\/fonc.2023.1051232","article-title":"Best treatment options for occult breast cancer: a meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"R10-20260513","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.surg.2023.03.020","article-title":"De-escalation of surgery for occult breast cancer with axillary metastasis","volume":"174","author":"Holt","year":"2023","journal-title":"Surgery"},{"key":"R12-20260513","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1245\/s10434-017-5928-x","article-title":"Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the national cancer database","volume":"24","author":"Hessler","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R13-20260513","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12893-022-01472-8","article-title":"Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study","volume":"22","author":"Zhao","year":"2022","journal-title":"BMC Surg"},{"key":"R14-20260513","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.2147\/CMAR.S169019","article-title":"Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R15-20260513","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3389\/fonc.2020.01420","article-title":"Different clinicopathological characteristics and prognostic factors for occult and non-occult breast cancer: analysis of the SEER database","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"key":"R16-20260513","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.breast.2010.02.007","article-title":"Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors","volume":"19","author":"Chia","year":"2010","journal-title":"Breast"},{"key":"R17-20260513","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1309\/TDP92PQLDE2HLEET","article-title":"Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity","volume":"127","author":"Bhargava","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R18-20260513","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAI.0000000000000186","article-title":"The novel marker GATA3 is significantly more sensitive than traditional markers mammaglobin and GCDFP15 for identifying breast cancer in surgical and cytology specimens of metastatic and matched primary tumors","volume":"24","author":"Sangoi","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R19-20260513","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.09.011","article-title":"GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors","volume":"26","author":"Yang","year":"2017","journal-title":"Ann Diagn Pathol"},{"key":"R20-20260513","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.semdp.2022.04.002","article-title":"Immunohistochemical markers for distinguishing metastatic breast carcinoma from other common malignancies: update and revisit","volume":"39","author":"Ding","year":"2022","journal-title":"Semin Diagn Pathol"},{"key":"R21-20260513","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41379-020-00692-8","article-title":"TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer","volume":"34","author":"Ai","year":"2021","journal-title":"Mod Pathol"},{"key":"R22-20260513","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13000-025-01623-4","article-title":"Trichorhinophalangeal syndrome type 1 (TRPS1) in breast pathology: diagnostic utility and pitfalls","volume":"20","author":"Hashmi","year":"2025","journal-title":"Diagn Pathol"},{"key":"R23-20260513","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000522538","article-title":"Quality issues in diagnostic immunohistochemistry in breast pathology","volume":"89","author":"Hoda","year":"2022","journal-title":"Pathobiology"},{"key":"R24-20260513","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1245\/s10434-016-5104-8","article-title":"Optimal surgical management for occult breast carcinoma: a meta-analysis","volume":"23","author":"Macedo","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R25-20260513","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjsurg.2019.11.023","article-title":"Treatment for occult breast cancer: a propensity score analysis of the National Cancer Database","volume":"220","author":"Tsai","year":"2020","journal-title":"Am J Surg"},{"key":"R26-20260513","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1245\/s10434-020-08227-w","article-title":"Surgical management of the axilla in patients with occult breast cancer (cT0 N+) after neoadjuvant chemotherapy","volume":"27","author":"Cohen","year":"2020","journal-title":"Ann Surg Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:00:17Z","timestamp":1778655617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002534"}},"subtitle":["Pathologic Features of an Uncommon Clinical Presentation in a Large Cohort"],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002534","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}